Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a ...

"These treatments aim to selectively eliminate autoreactive B cells responsible for auto-antibody production, potentially providing a long-term reduction in exacerbations. Autologous hematopoietic ...

Overall enabling the dual targeting of autoreactive CD19 positive B-cells and plasmablast, and CD70 positive dendritic cells, while the Dagger improves the allogeneic CAR-T survival and ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

response mediated by CD27+IgM+ B-cells exhibited persistent memory-like anti-MPO-IgM B-cells, suggesting a failure in autoreactive B-cell elimination, according to a study published in Nature ...